The Group aims to enhance its corporate value into the future as a global company and promotes its business
activities in line with the “NOF VISION 2030,” its strategic policy. In the first six months of the current fiscal year, which falls in the final stages of the 2025 Mid-Term Management Plan, a stage positioned for expanding profit, although demand declined in the Functional Chemicals Segment except for certain areas, raw materials for DDS drug formulations in the Pharmaceuticals, Medicals and Health Segment performed steadily, making steady progress against the annual plan.

The interim dividend has been set at ¥26 per share, and the amount allocated for the purchase of treasury stock has been set at ¥5,000 million. In addition, concerning the forecast of our consolidated financial results for the current fiscal year, net sales, operating income, ordinary income, and profit attributable to owners of parent are expected to exceed the results of the previous fiscal year.

The Group provides innovative products and services that meet new needs by responding swiftly to market changes. We will further strengthen our technological development foundation, enhance the specialization of our products and services, and improve quality management, thereby advancing as a corporate group with the spirit of a technology-driven venture company.

Today, the world is facing numerous challenges, including environmental issues such as climate change as well as human rights issues. Working toward the realization of a sustainable society is an obligation that all companies must address. The Group will continue to endeavor to create new value with the power of chemistry, and meet the expectations of all of our stakeholders, thereby continuing to deliver true value to society.

We kindly ask all shareholders for your continuing support.


November 2025

Koji Sawamura
President & Chief Executive Officer